Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis by Caroline D. M. Witjes et al.
REVIEW ARTICLE
Recently introduced biomarkers for screening of hepatocellular
carcinoma: a systematic review and meta-analysis
Caroline D. M. Witjes • Susanna M. van Aalten •
Ewout W. Steyerberg • Gerard J. J. M. Borsboom •
Robert A. de Man • Cornelis Verhoef • Jan N. M. IJzermans
Received: 22 November 2011 / Accepted: 20 April 2012 / Published online: 12 May 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract
Purpose Early detection of hepatocellular carcinoma
(HCC) is essential for improved prognosis and long-term
survival. To date, screening for HCC depends on serological
testing (alpha-fetoprotein, AFP) and imaging (ultrasono-
graphy), both of which are not highly sensitive. A meta-
analysis was performed to discuss recent developments in
biomarkers that may be effective in screening for HCC.
Methods A systematic search of PubMed, Embase, and
Web of Science was performed for articles published
between January 2005 and October 2010, and focusing on
biomarkers for HCC in urine, serum, or saliva. Data on
sensitivity and specificity of tests were extracted from each
included article and displayed with a summary ROC. A
meta-analysis was carried out in which the area under the
curve for each biomarker was used to compare the accu-
racy of different tests.
Results In seven well-defined studies, three biomarkers
were identified for potential use, namely, Golgi protein 73
(GP73), interleukin-6 (IL-6), and squamous cell carcinoma
antigen (SCCA). Comparison with AFP showed that GP73
was superior (p = 0.006; 95 % CL -0.23, -0.12), IL-6
was similar (p = 0.66; 95 % CL -0.31, 0.25), and SCCA
was inferior to AFP (p = 0.001; 95 % CL 0.12, 0.23).
Conclusion GP73 is a valuable serum marker that seems
to be superior to AFP and can be useful in the diagnosis and
screening of HCC. Although GP73 may improve the detection
and treatment of one of the most common malignancies
worldwide, additional research is required.
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Abbreviations
HCC Hepatocellular carcinoma
AFP Alpha-fetoprotein
GP73 Golgi protein 73
PIVKA II Prothrombin induced by vitamin K absence II
sROC Summary ROC
AUC Area under the curve
IL-6 Interleukin-6
SCCA Squamous cell carcinoma antigen
RU Relative units
Introduction
The incidence of hepatocellular carcinoma (HCC) is rising
in many countries [1]. Alpha-fetoprotein (AFP) levels and
ultrasonography are widely applied for HCC screening.
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However, AFP alone has a sensitivity of 60 % at a cut-off
value of 20 ng/mL, and ultrasonography has a sensitivity of
65–80 % with a specificity C90 % when used as a
screening test [1].
The lack of efficacious tests necessitates investigation
for new HCC markers. Recent studies have focused on tests
that can detect HCC, including tests for DCP, also known
as prothrombin induced by vitamin K absence II (PIVKA
II), the ratio of glycosylated AFP (L3 fraction) to total
AFP, alpha fucosidase, glypican 3, and HSP-70. However,
as sensitivity and specificity values of these serological
markers were low, they proved to be inadequate for HCC
screening purposes, even when combined [1].
General criteria for effective disease screening have
been proposed by the World Health Organization (WHO).
These criteria are as follows: the disease screened for
should represent a major cause of death, the natural history
of the disease should be well characterized, screening for
the disease should be cost-effective, and the screening test
should be acceptable to the population. In addition, facil-
ities for diagnosis and treatment should be available, and
there should be a treatment for the disease that improves
the outcome if the disease is detected at an early stage [2].
These WHO criteria are met for HCC [1, 3].
To define the present state-of-the-art technology for
HCC screening, we initiated a systematic review and meta-
analysis, and discuss biomarkers most likely to be intro-
duced as new instruments for HCC screening.
Materials and methods
Literature search strategy
A systematic search of PubMed, Embase, and Web of
Science was performed for articles published between
January 2005 and October 2010 (cut-off date 1 October
2010) and relevant to HCC biomarkers in urine, serum, or
saliva. In 2005, Bruix et al. [1, 4] published the AASLD
guidelines, which they updated in 2011. However, with
respect to screening tests, their paper did not report on new
findings [1]. Therefore, in the present study a new literature
search was initiated based on the search terms listed in
Table 1.
Table 1 Terms used in the systematic search for the present review
Database Search terms
Pubmed (hepatocellular carcinoma[mesh] OR hepatoma*[tw] OR liver cell neoplasm*[tw] OR hepatocellular neoplasm*[tw] OR liver
cell cancer*[tw]
OR hepatocellular cancer*[tw] OR liver cell tumo*[tw] OR hepatocellular tumo*[tw] OR liver cell carcinom*[tw] OR
hepatocellular carcinom*[tw]) AND
(biological markers[mesh] OR Biomarker*[tw] OR Biological Marker*[tw] OR Biologic Marker*[tw] OR Biochemical
Marker*[tw] OR Immunologic Marker*[tw]
OR Immune Marker*[tw] OR Laboratory Marker*[tw] OR Serum Marker*[tw] OR Clinical Marker*[tw]) AND (blood[mesh]
OR blood[sh] OR blood[tw] OR
serum*[tw] OR plasm[tw] OR plasma[tw] OR urine[mesh] OR urine[sh] OR urine*[tw] OR saliva[tw]) NOT (animals[mesh]
NOT humans[mesh]) AND
Limits Publication date: 2005-3000 OR entrance date: 2005-3000 AND
Language: English OR Dutch
Embase (((‘liver cell’ OR hepatocell*) NEAR/3 (neoplasm* OR cancer* OR tumo* OR carcinom*)):ti,ab,de) AND (marker/exp OR
(biological NEAR/3 marker*):ti,ab,de
OR biomarker*:ti,ab,de) AND (blood/exp OR blood:ti,ab,de OR serum*:ti,ab,de OR plasm:ti,ab,de OR plasma:ti,ab,de OR
urine*:ti,ab,de OR saliva:ti,ab,de)
Limits Publication date: 2005-present AND
Human
Language: English OR Dutch
Web of
Science
(hepatoma* OR liver cell neoplasm* OR hepatocellular neoplasm* OR liver cell cancer* OR hepatocellular cancer* OR liver
cell tumo* OR hepatocellular
tumo* OR liver cell carcinom* OR hepatocellular carcinom*) AND (Biomarker* OR Biological Marker* OR Biologic Marker*
OR Biochemical Marker* OR
Immunologic Marker* OR Immune Marker* OR Laboratory Marker* OR Serum Marker* OR Clinical Marker*) AND (blood
OR serum* OR plasm OR plasma
OR urine* OR saliva) NOT (animal* NOT human*)
Limits Publication date: 2005-present AND
Language: English
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Literature screening
Studies were evaluated for their relevance to our present
topic. Study selection was accomplished through four
levels of study screening (C.D.M.W. in consensus with
S.M.A) (Fig. 1). At level 1, studies were excluded for the
following reasons: review, letters, case reports, editorials,
and comments. At level 2, abstracts of all the studies
accepted at level 1 were reviewed for relevance. The full
text was obtained for relevant papers, as well as any cita-
tions for which a decision could not be made from the
abstract. At level 3, inclusion required a control group with
C10 cirrhotic patients (hepatitis B and/or hepatitis C and/or
alcohol abusers), C10 patients with a HCC, and C10
confirmed healthy persons. Finally, at level 4, those studies
that tested the biomarker in a second independent popula-
tion were included together with the studies that were a
continuation of studies included at level 3. All studies
without repeated measurements, as validation of their
method, were excluded.
Data extraction and critical appraisal
From each included article, we extracted data on study
design, study population, and test results. The level of
evidence of each article was scored using the Oxford
Centre for Evidence-based Medicine Level of Evidence
scale [5].
Data on sensitivity and specificity were extracted from
each included article. If percentages were not reported, the
sensitivity and specificity at several cut-off points were
taken from the ROC curve in the included manuscripts.
Statistics
Sensitivities and specificities of the included studies were
logistically transformed, and a linear regression line was
fitted through the resulting points. This line was then back-
transformed to obtain the summary ROC (sROC) curve,
according to the method described by Littenberg and Moses
in 1993 [6]. A conventional ROC curve describes the impact
of threshold in a single patient population. The sROC curve,
a compact description of the accuracy of the diagnostic test,
describes the test in many populations. Note that we did not
extrapolate the curve past the range of empiric data.
The area under the curve (AUC) for the biomarkers of
the included studies was taken from the reports. For each
biomarker, the pooled AUC was calculated using the
inverse standard errors as weights. This pooled AUC,
together with their similarly pooled standard error, was
used to compare the accuracy of the diagnostic tests. AFP
was considered as a reference for comparison to the other
markers and was compared with the pooled AUC of each
new biomarker using Student’s t test. SAS software (SAS
system 9.2, SAS Institute, Cary, NC, USA) was used to
perform the statistical analyses. A result was considered
statistically significant at a p value of \0.05.
Results
Among 2,822 articles identified by the initial search, seven
were within the scope of the study (Fig. 1) [7–13]. Two
articles described Golgi protein 73 (GP73) as a HCC bio-
marker [7, 8], two described interleukin-6 (IL-6) [9, 10], and
three described squamous cell carcinoma antigen (SCCA)
[11–13]. All identified studies provided level 2b evidence on
the Oxford Level of Evidence scale and included a control
group with C10 cirrhotic patients (hepatitis B and/or hepa-
titis C and/or alcohol abusers), C10 patients with a HCC, and
C10 confirmed healthy persons [5].
GP73
GP73, also named Golgi phosphoprotein 2 (GOLPH2), is a
400-amino acid, 73 kDa transmembrane glycoprotein that
normally resides within the cis-Golgi complex [7].
Marrero et al. tested GP73 in the sera of 352 patients, of
whom 144 had HCC, 152 had cirrhosis, and 56 did not
have any disease [7]. At the optimal cut-off point of 10Fig. 1 Flow diagram showing selection of the seven articles
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relative units (RU), the sensitivity of GP73 was 62 %, with
a specificity of 88 %.
A recent study by Mao et al. tested GP73 in the sera of
4,217 subjects: 789 with HCC, 427 who were HBV or
HCV carriers, 614 with cirrhosis, and 1,690 healthy con-
trols [8]. GP73 sensitivity was 74.6 % and specificity was
97.4 % at an optimal cut-off value of 8.5 RU. The sROC of
GP73 in these studies is shown as the gray dotted line in
Fig. 2.
IL-6
IL-6 is a pleiotropic cytokine playing a central role in
hematopoiesis, and in the differentiation and growth of a
number of cells with different histological origins [9, 10].
The expression of IL-6 on hepatocytes, its upregulation by
hepatitis B virus X protein, and its increased hepatic
expression in liver cirrhosis have made IL-6 an intriguing
cytokine to study in HCC [9].
Porta et al. [9] studied IL-6 in the sera of 90 patients: 30
with HCC, 30 with cirrhosis, and 30 healthy subjects. At
the cut-off of 12 pg/mL, they found a sensitivity of 73 %
with a specificity of 87 %.
Hsia et al. [10] also studied IL-6 in the sera of 128
patients, of whom 26 patients had HCC, 50 had chronic
HBV or HCV infection, and 29 were without any disease
(healthy controls). The authors found a sensitivity of 46 %
with a specificity of 95 % for IL-6 at a cut-off of 3 pg/mL.
The sROC of IL-6 of these studies is shown as the black
straight line in Fig. 2.
SCCA
SCCA, a component of the high molecular weight serine
protease inhibitors named serpins, is physiologically
expressed in the squamous epithelia [11–13]. Increased
levels have been detected in several epithelial cancers such
as those of the head, neck, cervix, and lung [11–13].
Giannelli et al. [11] tested SCCA in the sera of 251
patients: 120 with HCC, 90 with cirrhosis, and 41 healthy
subjects. At an SCCA cut-off of 0.368 ng/mL, the sensi-
tivity was 84 % with a specificity of 48 %.
In 2007, Giannelli et al. [12] reported on serum SCCA
testing in 961 patients at a cut-off of 3.8 ng/mL; a sensi-
tivity of 42 % with a specificity of 83 % was found.
In 2008, Hussein et al. [13] evaluated SCCA in the sera
of 94 patients, including 49 patients with HCC, 30 with
chronic liver disease without HCC, and 15 healthy persons.
They used several cut-off points for SCCA: 100 % sensi-
tivity and 7 % specificity were found at cut-off 0.3 ng/mL;
78 % sensitivity and 84 % specificity, at cut-off 1.5 ng/
mL; and 39 % sensitivity and 100 % specificity were found
at cut-off 3.5 ng/mL. The sROC of SCCA in these three
studies is shown as the black dotted line in Fig. 2.
AFP
Under physiological conditions, AFP is a fetal-specific gly-
coprotein with a molecular weight of around 70 kDa. It is
synthesized primarily by cells of the embryonic liver, of the
vitelline sac, and of the fetal intestinal tract in the first tri-
mester of pregnancy [14]. The serum concentration of AFP
declines rapidly after birth, and its expression is repressed in
adults [14]. In the pathological state of chronic liver disease,
particularly, that associated with a high degree of hepatocyte
regeneration, AFP can be expressed in the absence of cancer
[14]. All studies compared the performance characteristics
of their biomarker to those of AFP in differentiating HCC
from non-malignant chronic liver disease [14]. The seven
articles defined within the scope of this study all tested serum
AFP in their population. The sensitivity and specificity for
AFP are summarized in Table 2. The sROC of AFP of the
seven studies is shown as the gray straight line in Fig. 2.
SROC
The sROC is a method for summarizing discrepant data on
the accuracy of diagnostic technologies; it summarizes the
central tendency of a set of accuracy reports.
Comparing the ‘gold standard’ with the three new bio-
markers displayed that GP73 was superior to AFP
(p = 0.006; 95 % CL -0.23, -0.12), IL-6 was similar to
AFP (p = 0.66; 95 % CL -0.31, 0.25), and SCCA was
inferior to AFP (p = 0.001; 95 % CL 0.12, 0.23).
Fig. 2 The sROC with the sensitivity and 1-specificity of GP73,
AFP, IL-6, and SCCA
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Discussion
This systematic review has attempted to correlate recently
discovered biomarkers for HCC screening with AFP. Our
findings suggest an advantage of GP73 over AFP as a
serum marker for HCC screening. In our review process,
many papers were excluded because of limitations in study
design: mostly because of a poor definition of the under-
lying etiology and the absence of a healthy control group.
Due to our rigorous selection criteria, the review was
limited to seven studies with level 2b evidence, all testing
their biomarker in serum [5]. Preferably, HCC screening
should be performed using a non-invasive diagnostic test.
Although the field of tumor markers in HCC is rapidly
evolving, no ideal marker tested with a proper study design
currently exists.
Since HCC is among the cancers with the worst prog-
nosis, early diagnosis and treatment are essential for
effective treatment [1]. The use of serological markers in
patients at highest risk for developing HCC may decrease
HCC mortality. However, for many years AFP has been the
only standard serum marker for the detection of HCC,
despite its unsatisfactory sensitivity [1]. Therefore, several
new biomarkers (such as GP73, IL-6, and SCCA) have
been investigated for their diagnostic accuracy and poten-
tial clinical application.
Giannelli et al. reported SCCA to be a good biomarker
for discriminating early HCC from liver cirrhosis. Com-
bining the three studies reporting on SCCA in a meta-
analysis, we found SCCA to be inferior to AFP
(p = 0.001).
In this systematic review, our meta-analysis of publi-
cations reporting on IL-6 showed that the accuracy of IL-6
was similar to that of AFP (p = 0.66).
Recent studies have identified serum GP73 as a potential
biomarker for HCC. The study of Marrero et al. showed
GP73 to be promising but had a small sample size [7]. A
second study performed in medical centers in China and
the USA showed GP73 to be a valuable tumor marker for
HCC [8]. Combining both studies in our meta-analysis
showed GP73 to be superior to AFP (p = 0.006). Although
GP73 appears to be a better marker than AFP for diag-
nosing HCC, additional research is required that focuses on
GP73.
Mao et al. found the elevation of serum GP73 to be
modest in virus carriers, moderate in patients with cirrho-
sis, and dramatic in patients with HCC [8]. This indicates
that the performance of GP73 might depend on the etiology
of the underlying disease. This is important if one wants to
differentiate between non-malignant disease and early
HCC in; for instance, patients with chronic viral hepatitis.
The authors also claimed tumor recurrence to be correlated
with an elevated GP73 level in the blood [8]. Thus, besides
being an interesting screening test, GP73 might also be
useful as a surveillance test. The role of intrahepatic
metastasis of the original tumor versus the development of
de novo tumors could not be tested by Mao et al. The
authors found no effect based on tumor size and tumor
differentiation on the serum levels of GP73 [8].
The small amount of data available per paper on dif-
ferences in etiology, tumor recurrence, and tumor devel-
opment (numbers of tumors) precluded us from
establishing the performance of GP73 in relation to these
three parameters.
It would be interesting to examine whether combined
measurements of GP73 and AFP further increase the sen-
sitivity for detection of HCC. Although GP73 is a prom-
ising marker, more studies are warranted, especially
because this protein is detected by Western blot analysis
which hampers its reliability and availability in clinical
use. Further studies are needed to analyze and validate
early-stage HCC markers. Recently, Shang et al. [15]
evaluated osteopontin as a marker of early-stage HCC.
Although this study has some limitations, it is an important
first step in the evaluation of new markers of early-stage
HCC [15]. The next step should be large-scale validation to
determine whether osteopontin is superior to GP73 and to
analyze whether osteopontin in combination with GP73
complements screening tests.
In conclusion, GP73 is a valuable serum marker that is
superior to AFP and can be useful in the diagnosis and
screening of HCC. GP73 may improve the detection and
Table 2 Characteristics and
outcome measures of the
included studies describing
serum AFP levels in the patients
tested
AFP alpha-fetoprotein
Authors Year
published
No. of
patients
Cut-off value
AFP (ng/mL)
Sensitivity (%) Specificity (%)
Marrero et al. [7] 2005 352 112 25 97
Mao et al. [8] 2010 4,217 35 58 85
Porta et al. [9] 2008 90 12.8 63 88
Hsia et al. [10] 2007 128 20 62 88
Giannelli et al. [11] 2005 251 12.6 45 87
Giannelli et al. [12] 2007 961 18.8 41 94
Hussein et al. [13] 2008 94 7.7 90 93
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treatment of one of the most common malignancies
worldwide. More studies are needed to further elucidate the
influence of the etiology of disease on the signal strength of
GP73.
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